المؤلفون: Yan HF, Zheng CL, Li Z, Bao BW, Yang BW, Hou KZ, Qu XJ, Xiao JW, Che XF, Liu YP

المصدر: Cancer Management and Research, Vol Volume 15, Pp 1123-1124 (2023)

مصطلحات موضوعية: gastric cancer, prognostic marker, metastasis, nptx1, focal contacts, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/retraction-nptx1-promotes-metastasis-via-integrinfak-signaling-in-gast-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/dc7fc401cc81432b8f89662a11a29d1a

المؤلفون: Jing W, Song N, Liu YP, Qu XJ, Qi YF, Li C, Hou KZ, Che XF, Yang XH

المصدر: Cancer Management and Research, Vol Volume 11, Pp 6379-6396 (2019)

مصطلحات موضوعية: DNA methyltransferases 3a, pancreatic ductal adenocarcinoma, prognosis, proliferation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/dnmt3a-promotes-proliferation-by-activating-the-stat3-signaling-pathwa-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/5a920db28ede42ecbed442d4b37e613e

المؤلفون: Yan HF, Zheng CL, Li Z, Bao BW, Yang BW, Hou KZ, Qu XJ, Xiao JW, Che XF, Liu YP

المصدر: Cancer Management and Research, Vol Volume 11, Pp 3237-3251 (2019)

مصطلحات موضوعية: gastric cancer, prognostic marker, metastasis, NPTX1, focal contacts, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/nptx1-promotes-metastasis-via-integrinfak-signaling-in-gastric-cancer-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/99a51e109320443eab9af65966244e04

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Zheng CL; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Hou KZ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Wang AQ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Fang WX; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Yu ST; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Liang JE; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Qi HY; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Qu XJ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Liu YP; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China., Che XF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. xfche@cmu.edu.cn.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. xfche@cmu.edu.cn.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China. xfche@cmu.edu.cn.

المصدر: Chinese journal of integrative medicine [Chin J Integr Med] 2022 Jun; Vol. 28 (6), pp. 524-530. Date of Electronic Publication: 2020 Jul 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Chinese Journal of Integrated Traditional and Western Medicine Press Country of Publication: China NLM ID: 101181180 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1672-0415 (Print) Linking ISSN: 16720415 NLM ISO Abbreviation: Chin J Integr Med Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-6*/genetics , Interleukin-6*/metabolism , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics, Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Cyclin D1/genetics ; Cyclin D1/metabolism ; Cyclin D1/pharmacology ; Humans ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; STAT3 Transcription Factor/metabolism

المؤلفون: Gong H; The First Department of General Surgery, Shidong Hospital, Shanghai, P.R. China., Niu Q; The First Department of General Surgery, Shidong Hospital, Shanghai, P.R. China., Zhou Y; The First Department of General Surgery, Shidong Hospital, Shanghai, P.R. China., Wang YX; The First Department of General Surgery, Shidong Hospital, Shanghai, P.R. China., Xu XF; Department of Gastroenterology, Shidong Hospital, Shanghai, P.R. China., Hou KZ; The First Department of General Surgery, Shidong Hospital, Shanghai, P.R. China.

المصدر: Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 5241-5252.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101581063 Publication Model: Print Cited Medium: Internet ISSN: 2165-5987 (Electronic) Linking ISSN: 21655979 NLM ISO Abbreviation: Bioengineered Subsets: MEDLINE

مواضيع طبية MeSH: Colonic Neoplasms*/genetics , Colonic Neoplasms*/metabolism , Colonic Neoplasms*/pathology, Apoptosis/*genetics , Esterases/*genetics , Wnt Signaling Pathway/*genetics , fas Receptor/*genetics, Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Adult ; Aged ; Animals ; Colon/metabolism ; Colon/pathology ; Esterases/metabolism ; Female ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Middle Aged ; fas Receptor/metabolism

المؤلفون: Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Shen JM; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Qu JL; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Song N; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Che XF; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Hou KZ; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Shi J; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Zhao L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Shi S; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Liu YP; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Qu XJ; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China., Teng YE; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.

المصدر: Annals of translational medicine [Ann Transl Med] 2021 Feb; Vol. 9 (3), pp. 258.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: AME Publishing Company Country of Publication: China NLM ID: 101617978 Publication Model: Print Cited Medium: Print ISSN: 2305-5839 (Print) Linking ISSN: 23055839 NLM ISO Abbreviation: Ann Transl Med Subsets: PubMed not MEDLINE

المؤلفون: Xu L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Qu JL; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Song N; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Zhang LY; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Zeng X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Che XF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Hou KZ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Shi S; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Feng ZY; Boz Life Science Research and Teaching Institute, San Diego, CA 92109, USA., Qu XJ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Liu YP; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Teng YE; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

المصدر: Oncology reports [Oncol Rep] 2020 Dec; Vol. 44 (6), pp. 2443-2454. Date of Electronic Publication: 2020 Oct 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers, Tumor/*metabolism , Flap Endonucleases/*metabolism , Lung Neoplasms/*secondary , Neoplasm Recurrence, Local/*epidemiology , Triple Negative Breast Neoplasms/*pathology, Animals ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Breast/pathology ; Breast/surgery ; Cell Line, Tumor ; Cell Proliferation ; Disease-Free Survival ; Female ; Flap Endonucleases/analysis ; Flap Endonucleases/genetics ; Follow-Up Studies ; Gene Knockdown Techniques ; Humans ; Lymphatic Metastasis/pathology ; Mastectomy ; Mice ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prognosis ; RNA-Seq ; Tissue Array Analysis ; Triple Negative Breast Neoplasms/diagnosis ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/surgery ; Xenograft Model Antitumor Assays

المؤلفون: Lin H; The First Department of General Surgery, Shidong Hospital, Yangpu District, Shanghai, Anhui Medical University, University of Shanghai for Science and Technology, Shanghai, P.R. China. 3502006005@smmu.edu.cn., Hong YG, Zhou JD, Gao XH, Yuan PH, Xin C, Huang ZP, Zhang W, Hao LQ, Hou KZ

المصدر: European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2020 Oct; Vol. 24 (19), pp. 9940-9948.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Verduci Country of Publication: Italy NLM ID: 9717360 Publication Model: Print Cited Medium: Internet ISSN: 2284-0729 (Electronic) Linking ISSN: 11283602 NLM ISO Abbreviation: Eur Rev Med Pharmacol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms/*metabolism , Inhibin-beta Subunits/*metabolism , MicroRNAs/*metabolism , Proto-Oncogene Proteins c-akt/*metabolism , RNA, Long Noncoding/*metabolism, Cell Line ; Cell Proliferation ; Colorectal Neoplasms/pathology ; Humans ; Inhibin-beta Subunits/genetics ; RNA, Long Noncoding/genetics

المؤلفون: Cui H; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Xu L; Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Hou KZ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Che XF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Liu BF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Liu YP; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China., Qu XJ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

المصدر: Oncology letters [Oncol Lett] 2020 Aug; Vol. 20 (2), pp. 1573-1584. Date of Electronic Publication: 2020 Jun 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1792-1074 (Print) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE